Zonation, ligand and dose dependence of S1PR1 signalling in blood and lymphatic vasculature.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
01 Aug 2024
Historique:
received: 21 12 2023
revised: 03 06 2024
accepted: 12 06 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 1 8 2024
Statut: aheadofprint

Résumé

Circulating levels of sphingosine 1-phosphate (S1P), an HDL-associated ligand for endothelial cell (EC) protective S1P receptor-1 (S1PR1), are reduced in disease states associated with endothelial dysfunction. Yet as S1PR1 has high affinity for S1P and can be activated by ligand-independent mechanisms and EC-autonomous S1P production, it is unclear if relative reductions in circulating S1P impact endothelial function. It is also unclear how EC S1PR1 insufficiency, whether induced by ligand deficiency or by S1PR1-directed immunosuppressive therapy, affects different vascular subsets. We here fine-map the zonation of S1PR1 signalling in the murine blood and lymphatic vasculature, superimpose cell type-specific and relative deficiencies in S1P production to define ligand source- and dose-dependence, and correlate receptor engagement to essential functions. In naïve blood vessels, despite broad expression, EC S1PR1 engagement was restricted to resistance-size arteries, lung capillaries and high-endothelial venules (HEV). Similar zonation was observed for albumin extravasation in EC S1PR1 deficient mice, and brain extravasation was reproduced with arterial EC-selective S1pr1 deletion. In lymphatic EC, S1PR1 engagement was high in collecting vessels and lymph nodes and low in terminal capillaries that drain tissue fluids. While EC S1P production sustained S1PR1 signaling in lymphatics and HEV, hematopoietic cells provided ∼90% of plasma S1P and sustained signaling in resistance arteries and lung capillaries. S1PR1 signaling and endothelial function were both surprisingly sensitive to reductions in plasma S1P with apparent saturation around 50% of normal levels. S1PR1 engagement did not depend on sex or age, but modestly increased in arteries in hypertension and diabetes. Sphingosine kinase (Sphk)-2 deficiency also increased S1PR1 engagement selectively in arteries, which could be attributed to Sphk1-dependent S1P release from perivascular macrophages. This study highlights vessel subtype-specific S1PR1 functions and mechanisms of engagement and supports the relevance of S1P as circulating biomarker for endothelial function.

Identifiants

pubmed: 39086170
pii: 7725167
doi: 10.1093/cvr/cvae168
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Ilaria Del Gaudio (I)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.

Anja Nitzsche (A)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.

Kevin Boyé (K)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.

Philippe Bonnin (P)

Assistance Publique-Hôpitaux de Paris (AP-HP), Physiologie Clinique, Hôpital Lariboisière, Paris France.
Université Paris Cité, INSERM U1144, UFR de Pharmacie, Paris, France.

Mathilde Poulet (M)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.

Toan Quoc Nguyen (TQ)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.

Ludovic Couty (L)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.

Hoa T T Ha (HTT)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.

Dat T Nguyen (DT)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.

Amaury Cazenave-Gassiot (A)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.

Khaoula Ben Alaya (K)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.

Patrice Thérond (P)

Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Biochimie, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
UFR de Pharmacie, EA 4529, Châtenay-Malabry, France.

Jerold Chun (J)

Neuroscience Drug Discovery, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Markus R Wenk (MR)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.

Richard L Proia (RL)

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Institutes of Health, Bethesda, MD, USA.

Daniel Henrion (D)

Angers University, MitoVasc Department, Team 2 (CarMe), Angers University Hospital (CHU of Angers), CNRS, INSERM U1083, Angers, France.

Long N Nguyen (LN)

Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.

Anne Eichmann (A)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.
Yale University School of Medicine, Department of Internal Medicine and Cellular and Molecular Physiology, New Haven, USA.

Eric Camerer (E)

Université de Paris, Paris Cardiovascular Research Centre, INSERM U970, Paris, France.

Classifications MeSH